|
pA2
online
© Copyright 2003 The British Pharmacological Society
|
072P
University of Surrey
Summer Meeting June 2003
|
Investigation
of endegonous A2B adenosine receptor-evoked
Ca2+ signalling in human embryonic
kidney (HEK) cells using a fluorescence integrayted platre reader
(FLIPR)
AM Jackson1,
J Stables2,
SJ Hill1&
SPH Alexander1,
1Institute
of Cell Signalling & School of Biomedical Sciences, University
of Nottingham Medical School, Nottingham, NG7 2UH & 2GlaxoSmithKline,
Gunnels Wood Road, Stevenage, SG1 2NY.
|

Print abstract
Search PubMed
for:
Jackson AM
Stables
J
Hill
SJ
|
The A2B
adenosine receptor couples primarily to the stimulation of adenylate cyclase,
but is also able to evoke increases in [Ca2+]i
(Fredholm et al., 2001). Previous investigations using HEK cells
over-expressing human A2B
receptors demonstrated A2B-mediated
increases in [Ca2+],subi
that were attributed to Ca2+ release
resulting from phospholipase C activation (Linden et al., 1999).
HEK cells express A2B
receptors endogenously (Cooper et al., 1997), so the aim of the
present study was to investigate changes in [Ca2+]i
mediated by endogenous A2B
receptors in HEK cells.
HEK cells were grown essentially as described previously (Jackson et al., 2001). cAMP & inositol phosphates accumulations were determined
using [3H]-adenine or [3H]-inositol
pre-labeling, respectively, followed by column chromatography, as described
previously (Jackson et al., 2001). Changes in [Ca2+]i
were measured using a FLIPR®, in which cells were stimulated with
carbachol (CCh, 10-8-10-3
M) or buffer, followed after 330 seconds by NECA (5'-N-ethylcarboxamiodadenosine,
10-9-10-4
M), under Ca2+-containing or Ca2+-free
conditions as described previously (Jackson et al., 2001). Unless
otherwise stated, data represent the mean ± s.e.mean. of three
experiments.
NECA evoked substantial increases in [Ca2+]i
following pre-stimulation with CCh under both Ca2+-containing
& Ca2+-free conditions. Following
pre-stimulation with 1 µM CCh, pEC50
values for NECA-evoked increases in [Ca2+]i
were 6.22 ± 0.65 & 7.04 ± 0.01, with responses to 100
µM NECA of 26 ± 3 & 27 ± 2 % of a 1 mM CCh response,
under Ca2+-containing & Ca2+-free
conditions, respectively. 100 µM NECA failed to evoke increases
in inositol phosphates (IP) accumulation, or influence CCh-evoked increase
in IP accumulation (116 ± 15 % of 1 mM CCh response). Pre-incubation
with muscarinic receptor antagonists (1 µM) prior to the CCh pre-stimulus
reduced NECA-evoked [Ca2+]i
elevations, such that peak responses to NECA (10 µM) were 29 ±
1 (control), & 3 ± 0 (4-DAMP), 12 ± 1 (pirenzepine)
& 26 ± 2 % (methoctramine) of a control 1 mM CCh response.
Incubation with the ß-adrenoceptor agonist isoprenaline evoked a
concentration-dependent increase in cAMP generation in HEK cells (pEC50
= 7.32 ± 0.13, max. response = 24 ± 0 % of 10 µM NECA-evoked
cAMP response). Isoprenaline also evoked a concentration-dependent (pEC50
= 7.54 ± 0.28, maximum response = 27 ± 3 % 1 µM CCh
response) increase in [Ca2+]i
following pre-stimulation with 1 µM CCh, but not buffer. Forskolin
(1, 10 & 100 µM) also evoked significant (p<0.001) increases
in [Ca2+]i
following pre-simulation with CCh. 100 µM, but not 1 & 10 µM,
forskolin elicited a significant (p<0.05) increase in [Ca2+]i
following pre-stimulation with buffer alone (two-way ANOVA with Bonferroni
post-hoc tests).
Taken together, these results indicate coupling of the endogenous A2B
adenosine receptor in HEK cells to increases of intracellular calcium,
which appear to be mediated indirectly via elevation of cyclic AMP levels.
The visualisation of the A2B
(& ß-adrenoceptor) stimulation of [Ca2+]i
appears to be dependent on prior stimulation of cells with carbachol,
which in HEK 293 cells evokes increases in [Ca2+]i
via an M3
muscarinic receptor (Jackson et al., 2001).
We thank the MRC for financial support.
Cooper J et al. (1997).Br. J. Pharmacol. 122: 546-550.
Fredholm BB et al. (2001) Pharmacol.Rev. 53: 527-552.
Jackson AM et al. (2001) Br. J. Pharmacol. 134: 170P.
Linden J et al. (1999) Mol. Pharmacol. 56: 705-713.
|